BioNeutra Global Corporation
BGACF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.12 | 0.01 | -0.00 |
| FCF Yield | 0.54% | 5.15% | -31.79% | -24.10% |
| EV / EBITDA | -65.11 | -33.27 | -22.04 | 3.72 |
| Quality | ||||
| ROIC | 40.96% | 379.12% | -106.98% | 100.78% |
| Gross Margin | 27.57% | 30.94% | -1.86% | 61.42% |
| Cash Conversion Ratio | -0.08 | -0.36 | 1.46 | -0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -10.37% | -12.81% | -12.28% | -9.58% |
| Free Cash Flow Growth | -90.80% | 118.08% | -309.22% | -185.02% |
| Safety | ||||
| Net Debt / EBITDA | -41.91 | -20.93 | -12.61 | 3.07 |
| Interest Coverage | -1.43 | -4.23 | -3.17 | 8.15 |
| Efficiency | ||||
| Inventory Turnover | 0.84 | 0.49 | 0.55 | 0.32 |
| Cash Conversion Cycle | -437.51 | -501.00 | -315.82 | -793.63 |